Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR

Renaissance Technologies LLC acquired a new stake in Vor Biopharma Inc. (NASDAQ:VOR) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 128,839 shares of the company’s stock, valued at approximately $2,298,000. Renaissance Technologies LLC owned 0.24% of Vor Biopharma at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in VOR. UBS Group AG lifted its position in shares of Vor Biopharma by 284.8% during the 4th quarter. UBS Group AG now owns 292,118 shares of the company’s stock valued at $3,821,000 after acquiring an additional 216,209 shares during the period. Frazier Life Sciences Management L.P. acquired a new position in shares of Vor Biopharma in the 4th quarter valued at approximately $33,275,000. NEXTBio Capital Management LP bought a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $13,080,000. Simplify Asset Management Inc. bought a new stake in shares of Vor Biopharma during the 1st quarter worth approximately $955,000. Finally, Findell Capital Management LLC acquired a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $3,021,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Trading Down 1.3%

VOR opened at $23.37 on Tuesday. Vor Biopharma Inc. has a twelve month low of $6.50 and a twelve month high of $50.20. The company has a fifty day moving average of $17.80 and a 200-day moving average of $15.84.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. As a group, analysts forecast that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Wall Street Analyst Weigh In

VOR has been the subject of several research analyst reports. Wedbush boosted their price objective on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).